Compare OTIS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTIS | UTHR |
|---|---|---|
| Founded | 1853 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 25.1B |
| IPO Year | 2019 | 1999 |
| Metric | OTIS | UTHR |
|---|---|---|
| Price | $71.22 | $567.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $99.63 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 3.7M | 346.5K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | 0.87 | ★ 5.82 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $6.94 | $6.39 |
| Revenue Next Year | $4.83 | $14.18 |
| P/E Ratio | ★ $81.77 | $97.66 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $70.65 | $272.18 |
| 52 Week High | $101.42 | $609.35 |
| Indicator | OTIS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 49.06 |
| Support Level | N/A | $560.68 |
| Resistance Level | $92.15 | $603.63 |
| Average True Range (ATR) | 1.75 | 15.51 |
| MACD | -0.41 | -2.01 |
| Stochastic Oscillator | 7.93 | 14.17 |
Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.